Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia. NICE technology appraisal guidance 218
National Institute for Health and Care Excellence (NICE)
Record ID 32018013368
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta218
Year Published:
2011
URL for published report:
https://www.nice.org.uk/guidance/ta218
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Myelodysplastic Syndromes
- Leukemia, Myeloid, Acute
- Leukemia, Myelomonocytic, Chronic
- Azacitidine
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.